TNYA (Tenaya Therapeutics) Pretax Margin %: -8,565.33% (As of Mar. 2026)


TNYA Tenaya Therapeutics Inc TNYA
33 GF Score
Price $0.85
! 5 Warning Signs
View Full Analysis

What is Tenaya Therapeutics Pretax Margin %?

Tenaya Therapeutics TNYA -5.73% 33 Pretax Margin % is -8,565.33% as of Mar. 2026. GuruFocus rates TNYA with a GF Score™ of 33/100. The stock has 5 warning signs investors should review. Among 938 Biotechnology companies, Tenaya Therapeutics ranks worse than 96.91% on this metric.

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Tenaya Therapeutics's Pre-Tax Income for the three months ended in Mar. 2026 was $-19.27 Mil. Tenaya Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.23 Mil. Therefore, Tenaya Therapeutics's pretax margin for the quarter that ended in Mar. 2026 was -8,565.33%.

The historical rank and industry rank for Tenaya Therapeutics's Pretax Margin % or its related term are showing as below:

TNYA' s Pretax Margin % Range Over the Past 10 Years
Min: -36891.11   Med: 0   Max: 0
Current: -36891.11


TNYA's Pretax Margin % is ranked worse than
96.91% of 938 companies
in the Biotechnology industry
Industry Median: -89.375 vs TNYA: -36891.11

Tenaya Therapeutics  (NAS:TNYA) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Tenaya Therapeutics Pretax Margin % Related Terms


Tenaya Therapeutics Pretax Margin % Historical Data

* Premium members only.

The historical data trend for Tenaya Therapeutics's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tenaya Therapeutics Pretax Margin % Chart

Tenaya Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Pretax Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Tenaya Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -8,565.33

TNYA vs MIST, NRXP, TLSA: Pretax Margin % Comparison

For the Biotechnology subindustry, Tenaya Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tenaya Therapeutics Pretax Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tenaya Therapeutics's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Tenaya Therapeutics's Pretax Margin % falls into.


TNYA
33GF Score
Tenaya Therapeutics Inc TNYA
Pretax Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tenaya Therapeutics Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Tenaya Therapeutics's Pretax Margin for the fiscal year that ended in Dec. 2025 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-90.597/0
= %

Tenaya Therapeutics's Pretax Margin for the quarter that ended in Mar. 2026 is calculated as

Pretax Margin=Pre-Tax Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-19.272/0.225
=-8,565.33 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Pretax Margin % →
What does a Pretax Margin % of -8,565.33% mean?
Tenaya Therapeutics (TNYA) has a Pretax Margin % of -8,565.33% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Tenaya Therapeutics and its competitors. According to the industry distribution chart, Tenaya Therapeutics ranks #909 out of 938 companies in the Biotechnology industry, placing it in the top 96.9%.
Is Tenaya Therapeutics' Pretax Margin % too high?
Tenaya Therapeutics' current Pretax Margin % is -8,565.33%. Based on the distribution chart, Tenaya Therapeutics ranks #909 out of 938 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Tenaya Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Tenaya Therapeutics' Pretax Margin % compare to MIST and NRXP?
According to the Biotechnology industry distribution chart, Tenaya Therapeutics ranks #909 out of 938 companies for Pretax Margin %. This places Tenaya Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Tenaya Therapeutics and its competitors. Tenaya Therapeutics's current Pretax Margin % is -8,565.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tenaya Therapeutics stock overvalued right now?
Tenaya Therapeutics (TNYA) has a current Pretax Margin % of -8,565.33%. The current Pretax Margin % is -8,565.33%. Tenaya Therapeutics' overall GF Score™ is 33/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Tenaya Therapeutics (TNYA), the current Pretax Margin % is -8,565.33% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tenaya Therapeutics Business Description

Address 171 Oyster Point Boulevard, Suite 500, 5th Floor, South San Francisco, CA, USA, 94080
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.
33GF Score

Get the complete analysis for TNYA

Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.85
Price